Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed‐Dose Combination Approaches

Authors:
  • MWMatthew R. Weir
    Matthew R. Weir
  • OIon behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators
    on behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators

Abstract
Data from the Third National Health and Nutrition Examination Survey (NHANES III) demonstrate that only 11% of people with diabetes who are treated for high blood pressure achieve the blood pressure goal of p=0.001). At 3 months, more participants in the combination group achieved treatment goal (63% combination vs. 37% conventional; p=0.002). Data analysis at 3 months comparing blood pressure control rates between the fixed‐dose combination group (with out HCTZ) to the conventional group (receiving HCTZ) showed an even greater disparity in blood pressure goal achievement (87% combination without HCTZ vs. 37% conventional group with HCTZ; p=0.0001). We conclude that initial therapy with a fixed‐dose combination may be more efficacious than conventional monotherapy approaches for achieving blood pressure goals in the diabetic patient. A fixed‐dose combination approach appears as safe as the current conventional approaches.